Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T19:20:43.160Z.
Calculation as of: 2026-10-06T19:20:43.160Z.
Quote observation: 2026-10-06T19:20:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 66e3eaee1cdd755dffe0dd2f4d89b3fc137545160e5faabf240127d9674bae42
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$183.94M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$183.62M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$180.89M
Price/OCF Ratio
N/A
TTM Avg
28.65
3Y Avg
28.61
5Y Avg
28.61
Market Cap
$188.72M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$191.85M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$173.23M
Price/OCF Ratio
N/A
TTM Avg
21.38
3Y Avg
21.38
5Y Avg
21.38
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | $184.58M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $183.94M | N/A | N/A | N/A | N/A |
| Compass Therapeutics, Inc. (CMPX)vs › | $183.62M | N/A | N/A | N/A | N/A |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $180.89M | N/A | 28.65 | 28.61 | 28.61 |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $188.72M | N/A | N/A | N/A | N/A |
| Yarrow Bioscience Inc (YARW)vs › | $179.30M | N/A | N/A | N/A | N/A |
| RxSight, Inc. (RXST)vs › | $191.25M | N/A | N/A | N/A | N/A |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $191.85M | N/A | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.23M | N/A | 21.38 | 21.38 | 21.38 |
| Journey Medical Corporation (DERM)vs › | $171.80M | N/A | 32.12 | 27.16 | 27.16 |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
